Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | OC1CN(C1)C(=O)CC1(C2CC3CC1CC(C2)C3O)c1cccnc1 |TLB:12:11:8.13.14:16,7:8:16:10.11.17,19:8:10.12.11:14.15.16,THB:18:17:8.13.14:16,12:13:16:10.11.17,17:11:8:14.15.16,17:15:8:10.12.11,7:8:10.12.11:14.15.16,19:8:16:10.11.17,(62.71,-3.44,;63.86,-4.47,;65.4,-4.39,;65.47,-5.93,;63.94,-6.01,;66.62,-6.96,;66.29,-8.47,;68.08,-6.49,;69.23,-7.52,;70.43,-6.25,;71.75,-6.74,;73.15,-6.39,;72.14,-7.67,;70.73,-7.1,;70.72,-5.52,;71.76,-4.28,;70.42,-4.76,;73.17,-4.86,;74.45,-4.02,;69.21,-9.06,;67.87,-9.81,;67.85,-11.35,;69.18,-12.13,;70.52,-11.37,;70.53,-9.84,)| |